INSERM U1028, CNRS UMR5292, service de neuro-oncologie, hôpital neurologique, hospices civils de Lyon, Lyon Neuroscience Research Center, neuro-oncology and neuro-inflammation team, 59 boulevard Pinel, Lyon, France.
Rev Neurol (Paris). 2011 Oct;167(10):673-9. doi: 10.1016/j.neurol.2011.08.006. Epub 2011 Sep 8.
Diffuse low-grade gliomas (LGGs) in adults are progressive brain tumours that are radiologically characterized by slow and continuous growth that precedes anaplastic transformation. Standard treatment includes surgery and radiotherapy though the optimal timing of radiotherapy remains unsettled. Several retrospective and phase II studies have demonstrated that chemotherapy is also an interesting treatment option. However, several questions remain unanswered regarding its optimal use. The present review focuses on past, recent and ongoing developments in LGGs chemotherapy, including response assessment and potential predictive biomarkers of chemosensitivity.
成人弥漫性低级别胶质瘤（LGG）是一种进行性脑肿瘤，其放射学特征为在间变转化之前缓慢而持续的生长。标准治疗包括手术和放疗，但放疗的最佳时机仍未确定。几项回顾性和 II 期研究表明，化疗也是一种有趣的治疗选择。然而，关于其最佳使用仍有几个问题尚未得到解答。本综述重点介绍了 LGG 化疗的过去、最近和正在进行的发展，包括反应评估和潜在的化疗敏感性预测生物标志物。
